Pershing Square USA, Ltd.
PSUS News Today: Stay Updated with the Latest Pershing Square USA, Ltd. News in Real Time
Find PSUS news now at Meyka AI. Stay informed with the latest Pershing Square USA, Ltd. stocks updates, including price news, market analysis, and expert insights.

IFX.DE Stock Gains 2.47% on XETRA; Infineon at β¬49.18
IFX.DE stock rises 2.47% to β¬49.18 on XETRA. Infineon Technologies AG shows mixed signals with B- rating and upcoming earnings on May 6.

MLEC Insider Filing: Core Daniel Joaquin Director Stake, April 22, 2026
Director Core Daniel Joaquin files initial ownership of 933 ordinary shares in Moolec Science (MLEC) valued at $6,661.62 on April 15, 2026.

5IF.SI Stock Drops 13.6% on Apr 22, 2026 as Natural Cool Holdings Faces Pressure
5IF.SI stock falls 13.6% to S$0.089 on Apr 22, 2026. Natural Cool Holdings faces headwinds with weak fundamentals and high debt levels.

Canadian Flight Prices Jump April 22: Fuel Crisis Hits Travelers
Canadian flight prices rise 2.9% in March 2026 for the first time in 2 years amid fuel crisis and baggage fee hikes.

DW8.AX Stock Surges 2400% in April 2026 on ASX
DW8.AX stock price hits A$0.025 with massive 2400% gain. Beverage tech platform shows extreme volatility on ASX.

GNRSU Stock Crashes 99.99% on Pink Sheets, Greenrose Holdings Faces Delisting Risk
GNRSU stock plummets 99.99% to $0.000001 on PNK exchange. Greenrose Holdings faces severe liquidity crisis with market cap of just $13.

PASHUPATI.NS Stock Plunges 14.5% on NSE; Textile Maker Hits 22 Apr Close
PASHUPATI.NS stock fell 14.5% to INR 81.95 on NSE today. Pashupati Cotspin faces strong sell rating with weak technical signals.

GRBK Insider Trading: Cox Jeffery Dean Restricted Stock Units Filing April 22, 2026
Green Brick Partners insider Jeffery Dean files restricted stock units ownership. GRBK rated B+ by Meyka AI. SEC filing details.

Travere Kidney Drug Approved April 22: FDA Flexes Authority
Travereβs Filspari approved by FDA April 22 for rare kidney disease, opening a $3B market opportunity despite limited efficacy data.